Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM – Research Report), Orthofix (OFIX – Research Report) and Medtronic (MDT – Research Report).
Dexcom (DXCM)
BTIG analyst Marie Thibault reiterated a Buy rating on Dexcom yesterday and set a price target of $150.00. The company’s shares closed last Tuesday at $121.78.
According to TipRanks.com, Thibault is a 1-star analyst with an average return of
Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $149.00, representing a 21.1% upside. In a report issued on March 1, Piper Sandler also maintained a Buy rating on the stock with a $150.00 price target.
See today’s best-performing stocks on TipRanks >>
Orthofix (OFIX)
BTIG analyst Ryan Zimmerman maintained a Hold rating on Orthofix yesterday. The company’s shares closed last Tuesday at $13.00.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of
The the analyst consensus on Orthofix is currently a Hold rating.
Medtronic (MDT)
In a report issued on March 1, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Medtronic, with a price target of $92.00. The company’s shares closed last Tuesday at $84.60.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medtronic with a $93.75 average price target, implying a 9.7% upside from current levels. In a report issued on February 20, J.P. Morgan also maintained a Hold rating on the stock with a $88.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DXCM:
- DexCom call volume above normal and directionally bullish
- Dexcom Finalizes Stock Warrant Termination and Equity Deals
- Coleman’s Tiger Global bought Broadcom and DexCom during Q4
- A New Cause for Concern: Dexcom Adds a New Natural and Human Disruptions Risk
- DexCom price target raised to $160 from $110 at TD Cowen
